Patents Assigned to Abraxis BioScience, Inc.
-
Patent number: 8598180Abstract: Compositions comprising tetrahydroindolone derivatives in which the tetrahydroindolone moiety is covalently linked to a substituted arylpiperazine moiety and methods for treating neurological and psychiatric conditions using such compositions are disclosed.Type: GrantFiled: August 6, 2010Date of Patent: December 3, 2013Assignee: Abraxis Bioscience, Inc.Inventors: David Reed Helton, David Brian Fick, Jason Paul Sharp, Ernest H. Pfadenhauer
-
Publication number: 20110196026Abstract: The present invention provides stable pharmaceutical compositions of poorly water soluble pharmaceutical agents and stabilizing agents which function to increase stability of the compositions. The use of stabilizing agents provide extended stability of nanoparticle suspensions and other formulations of poorly water soluble pharmaceutical agents such as docetaxel under certain conditions, for example upon dilution for administration.Type: ApplicationFiled: September 2, 2010Publication date: August 11, 2011Applicant: Abraxis BioScience, Inc.Inventors: Tapas De, Neil P. Desai, Andrew Yang, Zachary Yim, Patrick Soon-Shiong
-
Publication number: 20100226996Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.Type: ApplicationFiled: October 26, 2006Publication date: September 9, 2010Applicant: Abraxis BioScience, Inc.Inventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
-
Publication number: 20100160448Abstract: The present invention provides novel 2,6-diisopropyl phenol 2,6-diisopropyl phenol analogs and sterile, stable pharmaceutical compositions of 2,6-diisopropyl phenol 2,6-diisopropyl phenol and analogs thereof useful as an antioxidant in the treatment of ischemic injury including stroke and other cerebral injury. 2,6-diisopropyl phenol or its analogs are administered in a dosage effective to produce blood levels and brain levels of the drug that can prevent free radical damage associated with ischemic injury.Type: ApplicationFiled: February 17, 2006Publication date: June 24, 2010Applicant: Abraxis BioScience, Inc.Inventors: Neil P. Desai, Chunlin Tao, Cheng Zhi Yu, Vuong Trieu, Patrick Soon-Shiong
-
Publication number: 20090291139Abstract: The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.Type: ApplicationFiled: March 29, 2007Publication date: November 26, 2009Applicant: Abraxis Bioscience, Inc.Inventors: Vuong Trieu, Neil P. Desai, Patrick Soon-Shiong
-
Patent number: 7586008Abstract: The invention provides para substituted dialkylphenol derivatives of propofol. The invention further provides pharmaceutical compositions comprising such analogs, methods for preparing such analogs, and methods of using such analogs to induce general anesthesia, sedation, and/or hypnotic or sleep effects in a patient.Type: GrantFiled: July 9, 2008Date of Patent: September 8, 2009Assignee: Abraxis Bioscience, Inc.Inventors: Chunlin Tao, Cheng Zhi Yu, Neil P. Desai, Vuong Trieu
-
Publication number: 20090042303Abstract: The invention provides an accurate, economical, automatable, high throughput method for the determination of the concentration of glycosaminoglycan anticoagulants, including low molecular weight heparin (LMWH) anticoagulants, in aqueous solutions. A method for cleaning a unit of manufacturing equipment used in the preparation of a LMWH to obtain an acceptable residual concentration of LMWH is further provided.Type: ApplicationFiled: July 24, 2008Publication date: February 12, 2009Applicant: ABRAXIS BIOSCIENCE, INC.Inventor: Ralph YAMAMOTO
-
Publication number: 20080275100Abstract: The invention provides para substituted dialkylphenol derivatives of propofol. The invention further provides pharmaceutical compositions comprising such analogs, methods for preparing such analogs, and methods of using such analogs to induce general anesthesia, sedation, and/or hypnotic or sleep effects in a patient.Type: ApplicationFiled: July 9, 2008Publication date: November 6, 2008Applicant: ABRAXIS BIOSCIENCE, INC.Inventors: Chunlin TAO, Cheng Zhi YU, Neil P. DESAI, Vuong TRIEU
-
Publication number: 20080255035Abstract: The invention provides methods of treating a mammalian tumors comprising combination therapy with SPARC polypeptides, an angiogenesis inhibitor and paclitaxel. The invention provides also methods of treating a mammalian tumors comprising combination therapy with SPARC polypeptides and paclitaxel. Further, the invention produces kits and methods to predict therapy responses.Type: ApplicationFiled: April 14, 2008Publication date: October 16, 2008Applicant: Abraxis BioScience, Inc.Inventors: Vuong Trieu, Neil P. Desai
-
Publication number: 20080234246Abstract: Analogs of geldanamycin (an ansamycin), pharmaceutical formulations comprising such analogs, and methods of use (e.g., treating tumors).Type: ApplicationFiled: November 15, 2007Publication date: September 25, 2008Applicant: Abraxis BioScience, Inc.Inventors: Chunlin Tao, Hongna Han, Xiaowen Sun, Neil Desai, Patrick Soon-Shiong
-
Publication number: 20080182258Abstract: The invention provides for SPARC polypeptides with a mutation corresponding to a deletion of the third glutamine in the mature form of the human SPARC protein, nucleic acids encoding such polypeptides, antibodies against such polypeptides, and methods of the use of such polypeptides, nucleic acids, and antibodies.Type: ApplicationFiled: December 26, 2007Publication date: July 31, 2008Applicant: Abraxis BioScience, Inc.Inventors: Vuong Trieu, Neil P. Desai, Patrick Soon-Shiong
-
Publication number: 20080176853Abstract: The invention provides for Triazine derivatives and their use to modulate protein kinase activity in a variety of conditions and diseases.Type: ApplicationFiled: December 14, 2007Publication date: July 24, 2008Applicant: Abraxis BioScience, Inc.Inventors: Chunlin Tao, Qinwei Wang, Neil P. Desai, Patrick Soon-Shiong
-
Publication number: 20080171687Abstract: Sterile, stable pharmaceutical formulations of poorly water-soluble drugs dissolved in dimethyl isosorbide, a water-miscible solvent, as well as methods for their preparation and administration.Type: ApplicationFiled: September 16, 2005Publication date: July 17, 2008Applicant: Abraxis Bioscience, Inc.Inventors: Neil P. Desai, Chunlin Tao, Andrew Yang, Bridget Beal-Grim, Tapas De, Patrick Soon-Shiong
-
Publication number: 20080132582Abstract: Sterile, stable pharmaceutical formulations of emulsions of neat propofol or propofol dissolved in a solvent and containing no preservative are provided that comprise optimal amounts of surfactants such as lecithin and solvent such as soybean oil, with a suitable pH range to prevent significant growth of microorganisms for at least 24 hours after adventitious, extrinsic contamination. The lower amount of oil or absence (oil) in the formulation also allows chronic sedation over extended periods of time with a reduced chance of lipid overload in the blood.Type: ApplicationFiled: June 4, 2007Publication date: June 5, 2008Applicant: Abraxis BioScience, Inc.Inventors: Neil P. Desai, Andrew Yang, Tapas De, Sherry Xiaopei Ci, Patrick Soon-Shiong
-
Patent number: 7332568Abstract: The invention provides for SPARC polypeptides with a mutation corresponding to a deletion of the third glutamine in the mature form of the human SPARC protein, nucleic acids encoding such polypeptides, antibodies against such polypeptides, and methods of the use of such polypeptides, nucleic acids, and antibodies.Type: GrantFiled: February 17, 2006Date of Patent: February 19, 2008Assignee: Abraxis BioScience, Inc.Inventors: Vuong Trieu, Neil P. Desai, Patrick Soon-Shiong
-
Publication number: 20070208030Abstract: Compositions comprising tetrahydroindolone derivatives in which the tetrahydroindolone moiety is covalently linked to a substituted arylpiperazine moiety and methods for treating neurological and psychiatric conditions using such compositions are disclosed.Type: ApplicationFiled: September 27, 2004Publication date: September 6, 2007Applicant: Abraxis BioScience, Inc.Inventors: David Helton, David Fick, Ernest Pfadenhauer, Jason Sharp
-
Publication number: 20070191463Abstract: The invention provides 2 aryl substituted derivatives of melatonin. The invention further provides pharmaceutical compositions comprising such derivatives, methods for preparing such derivatives, and methods of using such derivatives to induce general anesthesia, sedation, and/or hypnotic or sleep effects in a patient, and to treat conditions affected by melatonin activity in a patient.Type: ApplicationFiled: December 23, 2004Publication date: August 16, 2007Applicant: Abraxis Bioscience, Inc.Inventors: Chunlin Tao, Cheng-Zhi Yu, Neil Desai, Vuong Trieu
-
Publication number: 20070185217Abstract: The invention provides para substituted dialkylphenol derivatives of propofol. The invention further provides pharmaceutical compositions comprising such analogs, methods for preparing such analogs, and methods of using such analogs to induce general anesthesia, sedation, and/or hypnotic or sleep effects in a patient.Type: ApplicationFiled: December 23, 2004Publication date: August 9, 2007Applicant: ABRAXIS BIOSCIENCE, INC.Inventors: Chunlin Tao, Cheng Yu, Neil Desai, Vuong Trieu
-
Publication number: 20070128290Abstract: In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful selection of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered.Type: ApplicationFiled: October 26, 2006Publication date: June 7, 2007Applicant: Abraxis BioScience, Inc.Inventors: Neil Desai, Patrick Soon-Shiong
-
Publication number: 20070129448Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serun albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharrmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.Type: ApplicationFiled: October 26, 2006Publication date: June 7, 2007Applicant: Abraxis BioScience, Inc.Inventors: Neil Desai, Patrick Soon-Shiong, Vuong Trieu